en>Walrush: Added ego replacement as a subjective effect.

2024-05-10T09:43:27Z

Added ego replacement as a subjective effect.

New page

{{Distinguish|Ephedrine}}
{{SummarySheet}}
{{SubstanceBox/Ephenidine}}

'''Ephenidine''' (also known as '''NEDPA''' and '''EPE''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[chemical class::diarylethylamine]] class. Ephenidine is an [[NMDA receptor antagonist]]<ref name="wallach">{{cite journal | vauthors=((Wallach, J.)), ((Kang, H.)), ((Colestock, T.)), ((Morris, H.)), ((Bortolotto, Z. A.)), ((Collingridge, G. L.)), ((Lodge, D.)), ((Halberstadt, A. L.)), ((Brandt, S. D.)), ((Adejare, A.)) | veditors=((Lee, J.)) | journal=PLOS ONE | title=Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues | volume=11 | issue=6 | pages=e0157021 | date=17 June 2016 | url=https://dx.plos.org/10.1371/journal.pone.0157021 | issn=1932-6203 | doi=10.1371/journal.pone.0157021}}</ref> that is structurally related to diarylethylamines like [[diphenidine]] and [[methoxphenidine]]. Notable effects include sedation, hallucinations, anesthesia, and out-of-body states, referred to as "dissociative anesthesia".

Ephenidine and related diarylethylamines have been studied in humans as treatments for neurotoxic injuries.<ref>{{cite web | url=https://www.surechembl.org/document/EP-0346791-B1/ | title=Patent EP 0346791 - 1,2-diarylethylamines for treatment of neurotoxic injury | via=SureChEMBL | publisher=G.D. Searle, LLC | date=6 April 1994 | author1=Nancy M. Gray | author2=Brian K. Cheng}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0968089609002624 | title=NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds |author1=Michael L. Berger |author2=Anna Schweifer |author3=Patrick Rebernik |author4=Friedrich Hammerschmidt | journal=Bioorganic & Medicinal Chemistry |date=May 2009 | volume=17 | issue=1 | pages=3456–3462 | doi=10.1016/j.bmc.2009.03.025 | pmid=19345586}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1689/abstract | title=Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers |author1=Jason Wallach |author2=Pierce V. Kavanagh |author3=Gavin McLaughlin |author4=Noreen Morris |author5=John D. Power |author6=Simon P. Elliott |author7=Marion S. Mercier |author8=David Lodge |author9=Hamilton Morris |author10=Nicola M. Dempster |author11=Simon D. Brandt | journal=Drug Testing and Analysis |date=May 2015 | volume=7 | issue=5 | pages=358–367 | doi=10.1002/dta.1689 | pmid=25044512}}</ref><ref>{{cite journal|first1=Andrew|last1=Thurkauf|first2=James|last2=Monn|first3=Marienna V.|last3=Mattson|first4=Arthur E.|last4=Jacobson|title=Structural and conformational aspects of the binding of aryl-alkyl amines to the phencyclidine binding site|url=http://archives.drugabuse.gov/pdf/monographs/95.pdf|journal=NIDA research monograph|date=1989|issn=1046-9516|pages=51–56|volume=95|first5=Kenner C.|last5=Rice|pmid=2561843}}</ref><ref>{{cite journal|first1=L. H.|last1=Goodson|first2=C. J. W.|last2=Wiegand|first3=Janet S.|last3=Splitter|title=Analgesics. I. N-Alkylated-1,2-diphenylethylamines Prepared by the Leuckart Reaction|url=http://pubs.acs.org/doi/abs/10.1021/ja01215a018|journal=Journal of the American Chemical Society|date=November 1946|pages=2174–2175|volume=68|issue=11|doi=10.1021/ja01215a018|pmid=21002222}}</ref>
Recreational use was not documented until the 2013 U.K. [[arylcyclohexylamine]] ban, when it was released on the online [[research chemical]] market.<ref>{{cite journal | vauthors=((McLaughlin, G.)), ((Morris, N.)), ((Kavanagh, P. V.)), ((Power, J. D.)), ((O’Brien, J.)), ((Talbot, B.)), ((Elliott, S. P.)), ((Wallach, J.)), ((Hoang, K.)), ((Morris, H.)), ((Brandt, S. D.)) | journal=Drug Testing and Analysis | title=Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta - and para -substituted isomers: Characterization of 2-, 3- and 4-methoxydiphenidine isomers | volume=8 | issue=1 | pages=98–109 | date= January 2016 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1800 | issn=19427603 | doi=10.1002/dta.1800}}</ref> It was marketed alongside [[diphenidine]] and [[methoxphenidine]] as a substitute for [[methoxetamine]] ('''MXE''') despite users claiming markedly different effects.

Very little data exists about the pharmacological properties, metabolism, and toxicity of ephenidine, and it has an extremely limited history of human usage. The abuse of diarylethylamines has been linked to a number of fatal and non-fatal overdoses.<ref name="wallach" /> Many reports suggest that they may pose different risks than traditional dissociatives. It is highly advised to use [[harm reduction practices]] if using this substance.

==History and culture==
{{historyStub}}
Ephenidine has been described as a [[designer drug]]. Designer drugs are substances mimic the functional and structural features of commonly used illicit substances in order to circumvent government regulation.<ref>{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | volume=6 | issue=7–8 | pages=614–632 | date= August 2014 | issn=1942-7611 | doi=10.1002/dta.1620}}</ref><ref>{{cite journal | vauthors=((Van Hout, M. C.)), ((Hearne, E.)) | journal=Journal of Psychoactive Drugs | title=“Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine | volume=47 | issue=1 | pages=30–41 | date= March 2015 | issn=0279-1072 | doi=10.1080/02791072.2014.974002}}</ref>

==Chemistry==
Ephenidine is a molecule of the [[diarylethylamine]] class. It contains a substituted [[phenethylamine]] skeleton with an additional phenyl ring bound to Rα. An ethyl chain is bound to the terminal amine RN of the phenethylamine. Ephenidine is structurally analogous to [[diphenidine]] and [[MXP]], but is not a [[piperidine]] [[dissociative]]. Ephenidine shares a diphenylethylamine skeleton with [[diphenidine]] and [[MXP]], but lacks a piperidine substitution.

==Pharmacology==
{{Further|NMDA receptor antagonist}}
Ephenidine acts as an [[antagonist]] of the [[NMDA receptor]] (Ki = 66.4 nM).<ref>{{cite web | url=https://www.surechembl.org/document/EP-0346791-B1/ | title=Patent EP 0346791 - 1,2-diarylethylamines for treatment of neurotoxic injury | via=SureChEMBL | publisher=G.D. Searle, LLC | date=6 April 1994 | author1=Nancy M. Gray | author2=Brian K. Cheng}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0968089609002624 | title=NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds |author1=Michael L. Berger |author2=Anna Schweifer |author3=Patrick Rebernik |author4=Friedrich Hammerschmidt | journal=Bioorganic & Medicinal Chemistry |date=May 2009 | volume=17 | issue=1 | pages=3456–3462 | doi=10.1016/j.bmc.2009.03.025 | pmid=19345586}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1689/abstract | title=Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers |author1=Jason Wallach |author2=Pierce V. Kavanagh |author3=Gavin McLaughlin |author4=Noreen Morris |author5=John D. Power |author6=Simon P. Elliott |author7=Marion S. Mercier |author8=David Lodge |author9=Hamilton Morris |author10=Nicola M. Dempster |author11=Simon D. Brandt | journal=Drug Testing and Analysis |date=May 2015 | volume=7 | issue=5 | pages=358–367 | doi=10.1002/dta.1689 | pmid=25044512}}</ref><ref>{{cite journal|first1=Andrew|last1=Thurkauf|first2=James|last2=Monn|first3=Marienna V.|last3=Mattson|first4=Arthur E.|last4=Jacobson|title=Structural and conformational aspects of the binding of aryl-alkyl amines to the phencyclidine binding site|url=http://archives.drugabuse.gov/pdf/monographs/95.pdf|journal=NIDA research monograph|date=1989|issn=1046-9516|pages=51–56|volume=95|first5=Kenner C.|last5=Rice|pmid=2561843}}</ref><ref>{{cite journal|first1=L. H.|last1=Goodson|first2=C. J. W.|last2=Wiegand|first3=Janet S.|last3=Splitter|title=Analgesics. I. N-Alkylated-1,2-diphenylethylamines Prepared by the Leuckart Reaction|url=http://pubs.acs.org/doi/abs/10.1021/ja01215a018|journal=Journal of the American Chemical Society|date=November 1946|pages=2174–2175|volume=68|issue=11|doi=10.1021/ja01215a018|pmid=21002222}}</ref> The NMDA (N-methyl-D-aspartate) receptor is one of the major receptor subtypes for glutamate, the major excitatory neurotransmitter in the central nervous system (CNS). When NMDA channels are blocked, a loss of feeling (anesthesia), difficulty moving (immobilization), and at higher doses, the compound's equivalent of the “[[Visual_disconnection#Holes.2C_spaces_and_voids|K-hole]]” results.

Ephenidine also possesses weaker affinity for the [[dopamine]] and [[norepinephrine]] transporters (379 nM and 841 nM, respectively) as well as [[Sigma-1 receptor|σ1R]] (629 nM) and [[Sigma-2 receptor|σ2R]] (722 nM) binding sites.<ref>{{cite journal|first1=Heather|last1=Kang|first2=Pojeong|last2=Park|first3=Zuner A.|last3=Bortolotto|first4=Simon D.|last4=Brandt|title=Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties|url=http://www.sciencedirect.com/science/article/pii/S0028390816303392|journal=Neuropharmacology|doi=10.1016/j.neuropharm.2016.08.004|first5=Tristan|last5=Colestock|first6=Jason|last6=Wallach|first7=Graham L.|last7=Collingridge|first8=David|last8=Lodge|date=2016|volume=112|issue=Pt A|pages=144–149|pmid=27520396|pmc=5084681}}</ref>

==Subjective effects==
Ephenidine is reported to have a much more rapid onset and lower half-life when vaporized or smoked. When consumed this way, it is a suspected to be carcinogenic when excess heat is used. Some user reports have concluded that vaporization and plugging requires as low as 20% of what would be a common oral dose for that person.

{{Preamble/SubjectiveEffects}}
{{effects/base
|{{effects/physical|
*'''[[Effect::Stimulation]]''' - This compound produces stimulating effects at lower doses which are less intense than that of [[diphenidine]] or [[methoxphenidine]].
*'''[[Effect::Tactile disconnection]]'''
*'''[[Effect::Spatial disorientation]]
*'''[[Effect::Pain relief]]'''
*'''[[Effect::Cough suppression]]'''
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Nausea]]''' - This effect is inconsistently produced even within similar dosage ranges.
*'''[[Effect::Changes in felt gravity]]'''
*'''[[Effect::Spontaneous physical sensations]]''' - The ephenidine "body high" is a soft and pleasurable tingling sensation which is motionless and all-encompassing with no specific location.
*'''[[Effect::Tactile suppression]]''' - This partially to entirely suppresses one's sense of touch, creating feelings of numbness within the extremities. It is responsible for the anaesthetic properties of this substance.
*'''[[Effect::Motor control loss]]''' - A loss of gross and fine motor control alongside of balance and coordination is prevalent within the ephenidine experience and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless one is experienced) in case of falling over and injuring oneself.
*'''[[Effect::Perception of bodily lightness]]''' - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
*'''[[Effect::Gait alteration]]''' - Ephenidine typically causes movement such as walking to be perceived as automated and robotic.
*'''[[Effect::Physical autonomy]]'''
*'''[[Effect::Increased heart rate]]
*'''[[Effect::Orgasm suppression]]'''

}}
{{effects/visual|
====Suppression====
*'''[[Effect::Visual disconnection]]''' - This eventually results in the ephenidine equivalent of the famous "k-hole" or, more specifically, ''[[Visual disconnection#Holes, spaces and voids|holes, spaces and voids]]'' alongside of ''[[Visual disconnection#Structures|structures]]''. However, it is worth noting that particularly heavy doses must be consumed to reach the deepest state of this component in comparison to other more classical [[dissociative]]s such as [[ketamine]] or [[methoxetamine]].
*'''[[Effect::Visual acuity suppression]]'''
*'''[[Effect::Double vision]]''' - This component is prevalent at moderate to heavy dosages and makes reading impossible unless one closes an eye.
*'''[[Effect::Pattern recognition suppression]]''' - This effect generally occurs at higher dosages and makes one unable to recognize and interpret perceivable visual data.
*'''[[Effect::Frame rate suppression]]'''

====Distortions====
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Flowing|flowing]], [[Drifting#Breathing|breathing]] and [[Drifting#morphing|morphing]])'' - In comparison to other [[dissociative]]s, this effect is more prominent than [[ketamine]], [[MXE]], [[diphenidine]] and [[methoxphenidine]]. The visual drifting is simplistic, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style.
*'''[[Effect::Perspective distortions]]'''
*'''[[Effect::Environmental orbism]]'''
*'''[[Effect::Environmental cubism]]'''
*'''[[Effect::Scenery slicing]]'''

====[[Effect::Geometry]]====
The visual geometry found within ephenidine can be described as very distinct and psychedelic when compared to that of [[ketamine]], [[MXE]], [[methoxphenidine]] and [[diphenidine]]. It is considerably less detailed than that of [[DXM]]. It does not extend beyond level 5 and can be comprehensively described through its [[Visual_effects:_Geometry#Variations|variations]] as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.

====Hallucinatory states====
At high doses, ephenidine can produce a full range of high level hallucinatory states in a fashion that is less consistent and reproducible than that of many other commonly used [[psychedelic]]s. These effects include:

*'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other [[dissociative]]s, this effect can occur at heavy dosages, but is considerably less common than the same effect found within [[psychedelic]]s and [[deliriant]]s. It can be comprehensively described through its [[Visual_effects:_Internal_hallucinations#Variations|variations]] as delirious in believability, fixed in style, equal in new experiences and memory replays in content, autonomous in controllability and solid in style.

}}
|{{effects/cognitive|
The general head space of ephenidine is often described as particularly euphoric and clear-headed in comparison to that of [[DXM]] and [[ketamine]]. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:
*'''[[Effect::Thought acceleration]]''' and '''[[Effect::Thought deceleration|deceleration]]'''
*'''[[Effect::Depersonalization]]'''
*'''[[Effect::Derealization]]'''
*'''[[Effect::Dream potentiation]]'''
*'''[[Effect::Consciousness disconnection]]'''
*'''[[Effect::Memory suppression]]'''
**'''[[Effect::Ego death]]''' - This occurs at high dosage.
*'''[[Effect::Ego inflation]]''' - This occurs at low dosage and in a fashion that is less intense to that of [[mephedrone]], [[methamphetamine]] or [[cocaine]].
*'''[[Effect::Motivation enhancement]]''' - This occurs at low dosage.
*'''[[Effect::Analysis suppression]]
*'''[[Effect::Time distortion]]''' - This creates the illusion of time passing much more slowly than it would while sober. For example, a user could perceive that an hour or several hours have passed, over the course of only a few minutes.
*'''[[Effect::Cognitive euphoria]]
*'''[[Effect::Novelty enhancement]]'''
*'''[[Effect::Creativity enhancement]]'''
*'''[[Effect::Introspection]]'''
*'''[[Effect::Déjà vu]]'''
*'''[[Effect::Ego replacement]]'''
*'''[[Effect::Conceptual thinking]]'''
*'''[[Effect::Compulsive redosing]]'''
*'''[[Effect::Anxiety suppression]]'''
*'''[[Effect::Disinhibition]]'''
*'''[[Effect::Amnesia]]'''
*'''[[Effect::Increased music appreciation]]'''
*'''[[Effect::Personal meaning enhancement]]'''
*'''[[Effect::Decreased libido]]'''

}}
{{effects/auditory|
*'''[[Effect::Auditory enhancement]]'''
*'''[[Effect::Auditory suppression]]'''
*'''[[Effect::Auditory distortion]]'''
*'''[[Effect::Auditory hallucination]]'''

}}
{{effects/transpersonal|
*'''[[Effect::Existential self-realization]]'''

}}
}}
===Experience reports===
There are currently antecdotal reports which describe the effects of this compound within our [[experience index]].

{{#ask: [[Category:Ephenidine ]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:

*[https://www.erowid.org/experiences/subs/exp_Ephenidine.shtml Erowid Experience Vaults: Ephenidine]

==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational ephenidine use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because ephenidine has very little history of human usage.

Anecdotal reports from those who have tried ephenidine suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.
===Tolerance and addiction potential===
As with other NMDA receptor antagonists, the chronic use of ephenidine can be considered [[Addiction potential::moderately addictive with a high potential for abuse]] and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and [[withdrawal effects]] may occur if the user suddenly stops their usage.

Tolerance to many of the effects of ephenidine [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). Ephenidine presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of ephenidine all [[dissociative]]s will have a reduced effect.

===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Dissos}}

==Legal status==
{{legalStub}}
Ephenidine is illegal in some countries as a structural isomer of the banned opioid drug lefetamine.<ref>{{cite journal | vauthors=((Wink, C. S. D.)), ((Meyer, G. M. J.)), ((Wissenbach, D. K.)), ((Jacobsen-Bauer, A.)), ((Meyer, M. R.)), ((Maurer, H. H.)) | journal=Drug Testing and Analysis | title=Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS | volume=6 | issue=10 | pages=1038–1048 | date= October 2014 | issn=1942-7611 | doi=10.1002/dta.1621}}</ref><ref>{{cite journal | vauthors=((Wink, C. S. D.)), ((Meyer, G. M. J.)), ((Meyer, M. R.)), ((Maurer, H. H.)) | journal=Toxicology Letters | title=Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps | volume=238 | issue=3 | pages=39–44 | date=4 November 2015 | issn=1879-3169 | doi=10.1016/j.toxlet.2015.08.012}}</ref>

*'''Canada:''' As of March 2016, MT-45 and its analogues, one of which being ephenidine, are Schedule I controlled substances.<ref>{{Citation | vauthors=((Government of Canada, P. W. and G. S. C.)) | year=2016 | title=Canada Gazette – Regulations Amending the Food and Drug Regulations (Parts G and J — Lefetamine, AH-7921, MT-45 and W-18) | url=https://canadagazette.gc.ca/rp-pr/p2/2016/2016-06-01/html/sor-dors106-eng.html}}</ref> Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug.
*'''Germany''': Ephenidine is a controlled substance under the NpSG (''New Psychoactive Substances Act'') as a derivative of 2-Phenylethylamine.<ref>{{cite web|title=Neue-psychoaktive-Stoffe-Gesetz (NpSG)|trans-title=New Psychoactive Substances Act (NpSG)|url=https://www.gesetze-im-internet.de/npsg/NpSG.pdf|date=November 21, 2016|access-date=August 14, 2020|publisher=Bundesamt für Justiz [Federal Office of Justice]|language=de}}</ref>
*'''Sweden:''' Following a suggestion by Sweden's public health agency that ephenidine be classified as a hazardous substance on June 2015, ephenidine became a scheduled substance as of August 2015.<ref>{{Citation | title=Nyhetsarkiv — Folkhälsomyndigheten | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/}}</ref>
*'''Switzerland:''' Ephenidine is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' Ephenidine is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2016/9712">https://resmigazete.gov.tr/eskiler/2017/01/20170112-8.pdf</ref>
*'''United Kingdom:''' Ephenidine is illegal to produce, supply, or import in the U.K. under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>{{Citation | title=Psychoactive Substances Act 2016 | url=https://www.legislation.gov.uk/ukpga/2016/2/contents/enacted}}</ref>
*'''United States:''' Ephenidine could possibly be considered a positional isomer of SPA (lefetamine), which is a Schedule IV drug.<ref>DEA website | http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_14.htm</ref> However, the isomer clauses within the legal text of the Schedules have rarely, if ever, been used for prosecution.

==See also==

*[[Responsible use]]
*[[Research chemical]]
*[[Dissociative]]
*[[Diarylethylamine]]
*[[Diphenidine]]
*[[Methoxphenidine]]

==External links==

*[https://en.wikipedia.org/wiki/Ephenidine Ephenidine (Wikipedia)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=726 Ephenidine (Isomer Design)]

===Community===

*[http://www.bluelight.org/vb/threads/766110-The-Big-amp-Dandy-Ephenidine-(N-ethyl-1-2-diphenylethylamine)-Thread The Big & Dandy Ephenidine (N-ethyl-1,2-diphenylethylamine) Thread (Bluelight)]

==Literature==

*Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
*Wink, Carina S. D., et al. “Lefetamine‐Derived Designer Drugs N‐Ethyl‐1,2‐Diphenylethylamine (NEDPA) and N‐Iso‐Propyl‐1,2‐Diphenylethylamine (NPDPA): Metabolism and Detectability in Rat Urine Using GC‐MS, LC‐MSn and LC‐HR‐MS/MS.” ''Drug Testing and Analysis'', John Wiley & Sons, Ltd, 3 Mar. 2014, https://onlinelibrary.wiley.com/doi/abs/10.1002/dta.1621.
*“Toxicokinetics of Lefetamine and Derived Diphenylethylamine Designer Drugs-Contribution of Human Cytochrome P450 Isozymes to Their Main Phase I Metabolic Steps.” ''Toxicology Letters'', Elsevier, 11 Aug. 2015, <nowiki>https://www.sciencedirect.com/science/article/pii/S0378427415300333</nowiki>.
*“Ephenidine: A New Psychoactive Agent with Ketamine-like NMDA Receptor Antagonist Properties.” ''Neuropharmacology'', Pergamon, 9 Aug. 2016, https://www.sciencedirect.com/science/article/pii/S0028390816303392.
*Eiden, Céline, et al. “Ephenidine, Diphenidine, and Methoxphenidine Complications Reported to the French Addictovigilance Network.” ''Fundamental & Clinical Pharmacology'', John Wiley & Sons, Ltd (10.1111), 23 July 2018, https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12395.

==References==
{{#set:Featured=true}}

[[Category:Diarylethylamine]]
[[Category:Dissociative]]
[[Category:Research chemical]]

<references />

Ephenidine - Revision history

Sysop: 1 revision imported

en>Walrush: Added ego replacement as a subjective effect.

← Older revision		Revision as of 14:17, 1 November 2025
(No difference)